ProCE Banner Activity

OPAL: Phase II Trial of First-line Osimertinib Plus Platinum-Based Doublet Chemotherapy in EGFR-Mutated Advanced NSCLC

Slideset Download
In the phase II OPAL trial, first-line osimertinib combined with platinum-based chemotherapy demonstrated a high response rate and manageable safety in patients with EGFR-mutated advanced NSCLC.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab